2018 Press Releases

2018 | 2017 | 2016 | 2015 | 2014 | 2013

AMAG Pharmaceuticals Commends CMS for Clarifying Part D Coverage of Treatments for Moderate to Severe Dyspareunia Due to Menopause

WALTHAM, Mass., May 09, 2018 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today commended the recent action taken by the Centers for Medicare and Medicaid Services (CMS) to clarify statutory intent of section §1860D-2(e)(2)(A) of the Social Security Act, stating that drugs for the ... More > 

AMAG Pharmaceuticals Announces First Quarter 2018 Financial Results and Raises Full Year Financial Guidance

Strong first quarter execution with two FDA approvals and submission of a new drug application Conference call scheduled for 8:00 a.m. ET today WALTHAM, Mass., May 03, 2018 (GLOBE NEWSWIRE) --  AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today reported unaudited consolidated financial results for t... More > 

AMAG Pharmaceuticals Appoints J. Alan Butcher as Executive Vice President and Chief Business Officer

WALTHAM, Mass., May 02, 2018 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced the appointment of J. Alan Butcher as executive vice president and chief business officer effective immediately. He reports to William Heiden, president and chief executive officer. In his ... More > 

AMAG Pharmaceuticals to Present at Upcoming Investor Conferences

WALTHAM, Mass., April 27, 2018 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that company management will participate in the following investor conferences: Deutsche Bank Annual Health Care Conference Tuesday, May 8, 2018 at 8:40 a.m. ET Location: Boston, M... More > 

AMAG Pharmaceuticals to Host First Quarter 2018 Financial Results Conference Call and Webcast on Thursday, May 3, 2018 at 8:00 a.m. ET

WALTHAM, Mass., April 26, 2018 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that its first quarter 2018 financial results will be released on Thursday, May 3, 2018 before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m... More > 

AMAG Pharmaceuticals Submits a New Drug Application to the U.S. Food and Drug Administration for Bremelanotide for the treatment of Hypoactive Sexual Desire Disorder (HSDD) in Premenopausal Women

WALTHAM, Mass., March 26, 2018 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for bremelanotide, which AMAG in-licensed from Palatin Technologies, Inc. in February 2017. ... More > 

AMAG Pharmaceuticals to Present at Upcoming Investor Conferences

WALTHAM, Mass., March 05, 2018 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that company management will participate in the following investor conferences: Cowen and Company 38th Annual Health Care Conference Monday, March 12, 2018 at 1:30 p.m. ET Location: ... More > 

AMAG Reports 2017 Financial Results and Company Update

2017 GAAP Revenue Increased 15% Year-over-Year February 2018: Company Secures Two U.S. Food and Drug Administration (FDA) Approvals Conference Call Scheduled for 8:00 a.m. ET Today WALTHAM, Mass., Feb. 27, 2018 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today reported unaud... More > 

AMAG Pharmaceuticals to Host Fourth Quarter and Full Year 2017 Financial Results Conference Call and Webcast on Tuesday, February 27, 2018 at 8:00 a.m. ET

WALTHAM, Mass., Feb. 20, 2018 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that its fourth quarter and full year 2017 financial results will be released on Tuesday, February 27, 2018 before the U.S. financial markets open. Management will host a conference call and ... More > 

AMAG Pharmaceuticals Announces FDA Approval of Makena® (hydroxyprogesterone caproate injection) Subcutaneous Auto-Injector to Reduce the Risk of Preterm Birth in Certain At-Risk Women

Marks Second FDA Approval for AMAG this Month; Company to File NDA for Bremelanotide, A Novel Women’s Health Product, Later this Quarter WALTHAM, Mass., Feb. 14, 2018 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that the U.S. Food and Drug Administration (FDA) appr... More > 

AMAG Pharmaceuticals Announces FDA Approval of Supplemental New Drug Application (sNDA) for Feraheme® (ferumoxytol injection)

Feraheme is Now a Treatment Option for All Eligible Adult Patients with Iron Deficiency Anemia WALTHAM, Mass., Feb. 05, 2018 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that the U.S. Food and Drug Administration (FDA) has approved its application to broaden the ex... More > 

AMAG Pharmaceuticals Announces Preliminary 2017 Financial Results and Provides 2018 Guidance

WALTHAM, Mass., Jan. 08, 2018 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today provided a business update, including preliminary unaudited fourth quarter and full year 2017 financial results and 2018 financial guidance. The company will present further details at the 36th Annual ... More >